Decay induced de-chelation of positron-emitting electron-capture daughters and its use in preclinical PET. G.W. Severin1, L.K. Kristensen2, J. Fonslet1,

Slides:



Advertisements
Similar presentations
RADIO PHARMACY AN INTRODUCTION TO ITS CLINICAL APPLICATIONS By Jamie Al-Nasir, School of Pharmacy, Kingston university. Presented on 15/04/2008.
Advertisements

Lesson 16 Nuclear Medicine. What is Nuclear Medicine? Diagnosis and Treatment of Disease using small amounts of radio-nuclides (radiopharmaceuticals)
Medical Isotope Production and Use -with a special view on the need for ISOLDE and other big science facilities Mikael Jensen Professor, Applied Nuclear.
Nuclear Medicine. Nuclear Medicine Physiological Imaging Radioactive isotopes which emit gamma rays or other ionizing forms (half life for most is hours.
16 November 2004Biomedical Imaging BMEN Biomedical Imaging of the Future Alvin T. Yeh Department of Biomedical Engineering Texas A&M University.
Nuclear Medicine Spring 2009 FINAL. 2 NM Team Nuclear medicine MD Nuclear medicine MD Physicist Physicist Pharmacist Pharmacist Technologist Technologist.
Radionuclide generators for Nuclear Medicine
The Role of Copper in Nuclear Medicine Frederic Zoller NCSS 2006
Single Photon Computerized Tomography SPECT neuroimaging Seyed Kazem Malakouti, MD Faculty of Iran University of Medical Sciences Seyed Kazem Malakouti,
Radioisotopes in Medicine
January 2013 C14: Microdosimetry in nuclear medicine: emerging importance of Auger-electron data Alan Nichols University of Surrey, UK & Manipal University,
Chemistry and Imaging. Body Chemistry In order to be an effective health care professional, an individual must have an understanding of basic chemistry.
PET/CT & PET/MRI Radiopharmacy
Measurement of liver blood flow using [ 15 O]H 2 O and PET Literature review 7 th Modelling Workshop in Turku PET Centre, 20 th October 2005 Turku PET.
Targeted Gold Nanoparticles as Vascular Disrupting Agents during Radiation Therapy RI Berbeco 1, H Korideck 1, S Kunjachan 1, R Kumar 2, S Sridhar 2, A.
Introduction to Nuclear Medicine
9. DIAGNOSTIC NUCLEAR MEDICINE
Nuclear Medicine. The History Henri Becquerel 1896-Discovered mysterious “rays” Nobel Prize Marie Curie named mysterious rays “radioactivity”
Response of the sensors to different doses from tests in Israel Radiotherapy is used as a treatment in around 50% of cancer cases in the UK. Predominantly,
CP Biology Chapter 2 The Chemistry of Life. Chemicals make up ALL matter – living and nonliving. All life processes are chemical reactions. Chemical signals.
An Overview of Current and Propose Radioactive Nano- Particle Creation and Use L. Scott Walker Los Alamos National Laboratory 03/17/08.
Preclinical studies with non-standard and carrier-free radioisotopes from ISOLDE-CERN PHYSICS FOR HEALTH IN EUROPE WORKSHOP 2-4 February 2010 Gerd-J. BEYER.
Introduction to Healthcare and Public Health in the US Delivering Healthcare (Part 2) Lecture d This material (Comp1_Unit3d) was developed by Oregon Health.
Section.4: The Physics Behind the Treatment Lesson.9: Radiation and Treatment Objectives Recall and describe the origins of the radiation used for treatment.
Methodology PET and MRI scanning How do we investigate the brain?
Radioactivity Manos Papadopoulos Nuclear Medicine Department
By: Morgan Hammick BME 181 Section 2. What is a PET scan?  A positron emission tomography scan is an imaging test that uses a radioactive substance called.
Novel diagnostic and therapeutic radionuclides
Molecular Imaging & Positron Emission Tomography Nicholas Mulhern BME 281.
Nuclear Energy uses in medicine By; Jackie Kensey.
Physiological psychology Are boys better at three point turns than girls?
Nuclear Medicine Technique I 355 RAD L.Aya Ahmed Saeed.
Introduction to NM Omima Adam NMT 231. What is nuclear medicine NM Is the branch of medicine that uses radiation and nuclear properties of radionuclide's.
Nuclear Medicine and PET rev this is now slide 1do not print it to pdf things to do (check off when complete): add revision date to cover page.
Nuclear Medicine Physics and Equipment 243 RAD 1 Dr. Abdo Mansour Assistant Professor of radiology
Monday Case of the Day A) The treatment was successful: The bremsstrahlung SPECT (Fig 2) indicates that 90 Y was deposited in the tumor. B) The treatment.
Atoms for Health Prof. Dr. Werner Burkart Skolkovo Conference on: Accelerators and Radiation Technologies for the Future of Russia Saint Petersburg,
 Two reasons medical tracers can be placed in a body:  Diagnose disease or Treat Disease  In both cases, several factors must be accounted for:  Gamma.
Novel diagnostic and therapeutic radionuclides for the development
5.5 Medical Applications Using Radioactivity
Nuclear medicine Essential idea
Biodistribution of 212Pb Conjugated Trastuzumab in Mice
PhD Defence September 18th at 13:00 sharp Jesper Fonslet
"Approaches on the role of medical physicists in implementing the hybrid technologies in Nuclear Medicine". Papel de la FM en la implementación de los.
Sandun Perera, David Piwnica-Worms, and Mian M. Alauddin
Study of the kinetics of complex formation and in vivo stability of novel radiometal-chelate conjugates for applications in nuclear medicine Monika Stachura.
MGH Research Discoveries/Milestones
FRCR II - Radioactivity
Evolution of a “System” for Surgical Treatment of Adenocarcinomas
SMI-06 Workshop, Groningen,
The Synthesis of DFO-8 for Positron Emission Tomography
International Workshop on radiosensitization
Brain abnormalities in murders indicated by positron emission tomography (PET) Raine et al.
Staging of diffuse large B-cell lymphoma (DLBCL)
Function and Structure in
Unit 2 Scanning Techniques
CS Introduction to Medical Computing
Towards clickable radio-immunoconjugates
Lecture 3: Modes of Radioactive Decay
Radioisotopes in Medicine
Positron Emission tomography
II. Nuclear (Radioactive) Decay
Nuclear medicine Essential idea
Function and Structure in
9. DIAGNOSTIC NUCLEAR MEDICINE
9. DIAGNOSTIC NUCLEAR MEDICINE
CHAPTER 22 Nuclear Chemistry
In vivo silencing of Factor VII in liver hepatocytes.
The Design and Synthesis of DFO Derivatives for PET-Imaging
Development of 213Bi-labelled somatostatin analogues: Finding the optimal match between radiometal and chelator Ahenkorah Sa,c,d., Cleeren Fd., Ooms Ma.,
Presentation transcript:

Decay induced de-chelation of positron-emitting electron-capture daughters and its use in preclinical PET. G.W. Severin1, L.K. Kristensen2, J. Fonslet1, A.I. Jensen1, C.H. Nielsen2, D.R. Elema1, K. Johnston3, and U. Köster4   1Hevesy Laboratory, Center for Nuclear Technologies at the Technical University of Denmark, Frederiksborgvej 399, 4000 Roskilde, Denmark. 2Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Rigshospitalet and University of Copenhagen, Blegdamsvej 3, 2200 Copenhagen, Denmark. 3ISOLDE, CERN, CH-1211 Geneva 23, Switzerland 4Institut Laue-Langevin, 71 avenue des Martyrs, F-38042 Grenoble Cedex 9, France

Receptor-based Positron Emission Tomography (PET) 3-dimensional quantifiable tomography Used primarily in medical diagnosis. non-invasive. Requires positron emitting radionuclides to be covalently bound to a targeting molecule(vector). Images like these compel a transition from diagnositics to therapeutics Pfiefer et al. J Nucl Med. 2012 Aug;53(8):1207-15

Language ”vector” ”chelate” ”radiometal”

Work best if ‘internalized’ Imaging-to-Therapy If we can find cancer can we also treat it using the same vectors? Use vectors for drug delivery- Drug-loaded nanoparticles Radionuclides (Auger emitters) Can we make a PET technique to determine if therapeutic agents are internalized or not? Work best if ‘internalized’

”Internalization”

Small modifications change internalization status (DOTA)TATE (DOTA)LM3 Internalizes Doesn’t Internalize

Work best if ‘internalized’ Imaging-to-Therapy If we can find cancer can we also treat it using the same vectors? Use vectors for drug delivery- Drug-loaded nanoparticles Radionuclides (Auger emitters) Can we make a PET technique to determine if therapeutic agents are internalized or not? Work best if ‘internalized’

Electron Capture Decay is special, chemically. Enter ISOLDE 134Ce and 140Nd Nearly identical decay schemes to ‘short-lived’ positron emitting daughters. Nearly identical lanthanide chemistry. Difficult to produce and purify, except at ISOLDE. Match perfectly with DOTATATE Electron Capture Decay is special, chemically. 140Nd

140Nd EC decay creates 140Pr with an atomic hole that stabilizes by electron transitions which kick off more e-’s (Augers) and make more holes 140Nd 140Pr ultimately giving an Auger Cascade (e-’s:10eV-50keV)

The result of EC decay with our vector: 140Pr 140Nd

3 minute t1/2 clock begins ticking. Blood Flow β+ 140Pr

3 minute t1/2 clock begins ticking. Blood Flow 140Nd

3 minute t1/2 clock begins ticking. Blood Flow β+

Consequenses of the hypothesis 140Nd DOTATATE (internalizing) will give a PET signal that is localized on tumors (or cells expressing the receptor). 140Nd DOTALM3 (non-internalizing) will give a redistributed PET signal. Experimental procedure: Inject mice which have sst2+ tumors with each construct and compare the images when pre- and post- mortem (after ‘equilibration’ of the tracer distribution) Living PET Post-Mortem PET

Results: Post-Mortem Biodistribution (parent distribution) Pancreas can give a clean signal of the non-internalizing tracer Internalizing tracer clears very rapidly, and does not accumulate in the tumor Free-ion lanthanides also accumulate in the tumor! (and Liver is a ‘sink’ organ)

Cross your eyes: Tumor ratio (16h/PM) Tumor signal ratio: 16h/PM Non-internalizing (DOTALM3) Internalizing (DOTATATE) Control (NdChloride) 0.89±0.13 1.02±0.11 1.02±0.11

PET study: Non-Internalizing (DOTALM3) 16h = daughter distribution Post-Mortem = parent distribution 16 hours 3 % ID/g 0 % ID/g ”Source” ”Sink” Kidney Liver DOTALM3 0.78 ± 0.03 3.13 ± 0.82 DOTATATE 0.87 ± 0.10 1.29 ± 0.33 NdChloride 0.68 ± 0.03 0.96 ± 0.03

Reset the scale, and you can see the pancreas: Non-Internalizing DOTALM3 16 hours 8 % ID/g Ratio(16h/PM): 0.44±0.08 0 % ID/g 8 % ID/g 0 % ID/g Post-Mortem

Conclusions With careful optimization, internalization status might be determined using 140Nd or 134Ce PET. Requires high specific activity (at least in the sstr2 system) Determining the diffusion rates will depend upon having both 134Ce and 140Nd in high yield. Next steps: use a better perfused tumor model; introduce a ‘washout’ injection; triple coincidence w/44Sc (?). Thank you for your attention! Thanks to the behind-the-scene contributors at ISOLDE!